Skip to main content

PTC Therapeutics, Inc. (PTCT)

NASDAQ: PTCT · IEX Real-Time Price · USD
35.98 0.11 (0.31%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap2.54B
Revenue (ttm)471.89M
Net Income (ttm)-391.06M
Shares Out70.41M
EPS (ttm)-5.65
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume400,712
Open35.93
Previous Close35.87
Day's Range35.66 - 36.50
52-Week Range35.40 - 70.82
Beta1.22
AnalystsBuy
Price Target55.30 (+53.7%)
Est. Earnings DateOct 28, 2021

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the Euro...

IndustryBiotechnology
IPO DateJun 20, 2013
CEOStuart Peltz
Employees959
Stock ExchangeNASDAQ
Ticker SymbolPTCT
Full Company Profile

Financial Performance

In 2020, PTCT's revenue was $380.77 million, an increase of 24.04% compared to the previous year's $306.98 million. Losses were -$438.16 million, 74.2% more than in 2019.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price forecast is 55.30, which is an increase of 53.70% from the latest price.

Price Target
$55.30
(53.70% upside)
Analyst Consensus: Buy

News

Earnings Preview: PTC Therapeutics (PTCT) Q3 Earnings Expected to Decline

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

15 hours ago - Zacks Investment Research

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results

SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2021 financia...

1 week ago - PRNewsWire

PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility

SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing fa...

1 week ago - PRNewsWire

Tegsedi® Receives Innovative Drug Category Pricing in Brazil

SOUTH PLAINFIELD, N.J., Oct. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tegsedi® (inotersen) has successfully received Category 1 classification from Câmara de R...

1 week ago - PRNewsWire

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J., Sept. 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.

3 weeks ago - PRNewsWire

PTC Therapeutics' Rare Genetic Disease Gene Therapy Shows Durable Improvement Even At 5 Years

PTC Therapeutics Inc (NASDAQ: PTCT) presented a new analysis of five-year results of gene therapy, PTC-AADC. The data exhibited improvements in children with aromatic L-Amino acid decarboxylase (AADC) d...

3 weeks ago - Benzinga

Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy

SOUTH PLAINFIELD, N.J. , Sept. 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented a new analysis of five-year results that shows its novel gene therapy, PTC-AADC, leads to pr...

3 weeks ago - PRNewsWire

PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program

SOUTH PLAINFIELD, N.J., Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study.

1 month ago - PRNewsWire

STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenn...

SOUTH PLAINFIELD, N.J., Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented real-world results from the STRIDE patient registry demonstrating that treatment with Transla...

1 month ago - PRNewsWire

PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community

SOUTH PLAINFIELD, N.J., Sept. 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program.

1 month ago - PRNewsWire

PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences

SOUTH PLAINFIELD, N.J., Aug. 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Morgan Stanley V...

1 month ago - PRNewsWire

PTC Therapeutics' Waylivra Scores Approval In Brazil For Genetic Disorder

The Brazilian Health Regulatory Agency has approved PTC Therapeutics Inc's (NASDAQ: PTCT) Waylivra (volanesorsen) as the first treatment for familial chylomicronemia syndrome (FCS).  The approval is bas...

1 month ago - Benzinga

PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome

SOUTH PLAINFIELD, N.J., Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária)...

1 month ago - PRNewsWire

Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children ...

SOUTH PLAINFIELD, N.J., Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, "Gene Therapy in the Putamen for Curing AADC Deficiency and P...

1 month ago - PRNewsWire

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J., Aug. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Aug. 17, 2021, it approved non-statutory stock options to purchase an aggregate of 51,...

2 months ago - PRNewsWire

Recap: PTC Therapeutics Q2 Earnings

Shares of PTC Therapeutics (NASDAQ:PTCT) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 35.88% year over year to ($1.68), which b...

2 months ago - Benzinga

PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results

SOUTH PLAINFIELD, N.J., July 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2021.

2 months ago - PRNewsWire

Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Ev...

SOUTH PLAINFIELD, N.J., July 28, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the FIREFISH pivotal study were published in the New England Journ...

2 months ago - PRNewsWire

PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results

SOUTH PLAINFIELD, N.J., July 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 financi...

3 months ago - PRNewsWire

Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone

SOUTH PLAINFIELD, N.J., June 24, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit ...

3 months ago - PRNewsWire

Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy

SOUTH PLAINFIELD, N.J., June 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Japan by the Japanese Ministry of Health, Labor and ...

3 months ago - PRNewsWire

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J., June 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of 118,...

4 months ago - PRNewsWire

Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatme...

SOUTH PLAINFIELD, N.J., June 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic ...

4 months ago - PRNewsWire

Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors

SOUTH PLAINFIELD, N.J., June 9, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L.

4 months ago - PRNewsWire